Abstract. Inactivation of tumor-related genes by promoter hypermethylation is a common epigenetic event in the development of variety of tumors. Dermo1 (also called twist2) is a novel cancer-related gene which belongs to the basic helixloop-helix (bHLH) transcription factor family. Herein, we report that dermo1 expression was sporadically abrogated in human cancer cells by transcriptional silencing associated with CpG island promoter hypermethylation. Direct sequencing of bisulfite-modified DNA from a panel of seven human cancer cell lines (HL60, Molm14, MV4-11, RS4:11, MDM-BA231, H358, and H1299) revealed that CpG dinucleotides in the dermo1 promoter were methylated. RT-PCR results demonstrated that dermo1 CpG island hypermethylation was accompanied by a low basal dermo1 expression level. Our data implicate dermo1 as a tumor suppressor gene and a valuable molecular marker for human cancer.
Introduction
Epigenetic changes such as DNA methylation has important regulatory effects on gene expression, which involves CpG islands, located in the promoter regions of many genes (1, 2) . Aberrant methylation of CpG islands has been associated with the development of human tumor (3, 4) . In tumors from different patients, mutations that disrupt gene function often vary in genomic position over a wide region, whereas the position of CpG island promoter methylation is constant within an individual gene. The changes of methylation status of various gene promoters seem to be a common feature of malignant cells and these changes can occur early in the progression process. Therefore, detection of aberrant promoter hypermethylation of cancer-related genes has become an important tool for cancer diagnosis or detection of cancer recurrence (5) (6) (7) .
Dermo1 (also called Twist2) and Twist (Twist1) are highly conserved transcription factors which belong to the basic Helix-loop-helix (b-HLH) protein family, and their structures are highly homologous (8) (9) (10) . Twist can promote malignant tumor development and metastasis, and Twist activation in human cancers might both be a prognostic and/or predictive factor as well as a novel therapeutic target (11) (12) (13) . Twist CpG methylation is a useful biomarker in breast cancer diagnosis (14, 15) . However, very little is known regarding dermo1 function and the regulation model. dermo1 has only been found to be differentially methylated in CLL cells relative to Ig VH mutational statues (16) . The expression of dermo1 has been observed to downregulate p14arf thus antagonizing p53-induced apoptosis (17) .
In this study, we investigated methylated regulation profiles of dermo1 gene in leukemia, breast cancer and lung cancer cell lines to testify whether dermo1 methylation exist in different cancers. A pair of primers was designed to amplify a 450 bp fragment, which contains 16 CpG sites in the core promoter region of the dermo1 gene. PCR products of bisulfite-modified CpG islands were analyzed by DNA sequencing. Then two pairs of primers were designed to distinguish methylation from unmethylation DNA taking advantage of the sequence differences resulting from bisulfite modification. The relationship between promoter methylation and gene expression (assessed by reverse transcription PCR) were examined in seven human tumor cell lines (HL60, Molm14, MV4-11, RS4:11, MDM-BA231, H358 and H1299). These observations collectively suggest that promoter methylation of dermo1 might be a regular event in cancer. Our assay might have important implications in early detection and surveillance of cancer.
Materials and methods
Cell lines. Genomic DNA was obtained from seven cell lines: including four leukemia cancer cell lines (MV4-11, HL60, Molm14, and RS4:11), two lung cancer (H358 and H1299), one breast cancer (MDM-BA231), and one cervical cancer cell line (Hela). All cell lines were routinely cultured in RPMI-1640 medium (Gibco) containing with 10% fetal calf serum (Hyclone) at 5% CO 2 and 37˚C.
Bisulfite modification. DNA (2.0 μg) in a volume of 50 μl was denatured by NaOH (final concentration, 0.3 M) for 20 min at 42˚C. Thirty microliters of 10 mM hydroquinone (Sigma) and 520 μl of 4.2 M sodium bisulfite (Sigma) at pH 5.0, both freshly prepared, were added, and were incubated under mineral oil at 55˚C for 16 h. Modified DNA was purified using the Wizard clean-up system (Promega) and eluted into 180 μl of water. Modification was completed by NaOH (final concentration, 0.3 M) treatment for 15 min at 37˚C, followed by ethanol precipitation. DNA was resuspended in 40 μl TE and stored at -20˚C for use.
Bisulfite genomic sequencing and combined bisulfite restriction analysis. Primers were designed according to CpG island map of dermo1 gene. The forward primer was 5'-ggt cgcggtgtagattagttg-3' and the reverse primer was 5'-cta aactaaattactaaataattatc-3'. The PCR mixture contained BSP amplifications were performed in 50 μl reaction mixtures containing 4 μl bisulfite-treated DNA, 200 μM dNTPs, 100 nM primers, 2 mM MgCl 2 and 1 unit of FastTaq DNA polymerase (Roche). PCR conditions were: 95˚C for 2 min, 40 cycles of 95˚C for 50 sec, 60˚C for 50 sec, 72˚C for 1 min, and finally 5 min at 72˚C. The PCR products were purified from 1.5% agarose gels using the QIAquick PCR purified kit (Qiagen). For restriction analysis, PCR product was digested by BstUI restriction enzyme for 4 h at 60˚C and separated on a 3% agarose gel.
Methylation-specific PCR (MSP).
Methylation-specific PCR procedures were used to amplify bisulfite-modified genomic DNA. MSP primers directed against methylated and unmethylated alleles of dermo1 as follows: methylated primer (M-primer), forward: 5'-gttaagatttatataggtcg-3', reverse: 5'-cgcctcaavgtaaaaatcg-3'; unmethylated primer (U-primer), forward: 5'-gttaagatttatataggttg-3', reverse: 5'-cacctcaacataaa aatca-3'. PCR conditions were: 94˚C denaturing for 5 min; 94˚C for 45 sec, annealing at 60˚C for 45 sec, 72˚C 1 min. After purification from 2.0% agarose gels, PCR products were sequenced and analyzed to identify the methylated and unmethylated sequences.
Reverse transcription PCR assay. Total cellular RNA was extracted, isolated, and purified using the TRIzol reagent (Invitrogen) according to the manufacturer's protocol. The GAPDH transcripts in each sample were also amplified as internal controls to normalize the amount of dermo1-specific products. The primer sequences utilized were: GAPDH primer, forward: 5'-gtattgggcgcctggtcac-3', reverse: 5'-ctcctggaa gatggtgatgg-3'; dermo1 primer, forward: 5'-tcgagaggcagcc caagcgc-3', reverse: 5'-aggatccctagtgggaggcgga-3'. All of the reverse-transcriptase reactions were performed using SuperScript™ First-Strand synthesis system (Invitrogen). The PCR reaction mixture consisted of cDNA from 250 ng of total RNA, 200 pmol each primer, 0.2 mM dNTP, 1.5 mM Mg 2+ , 2.0 units of Taq DNA polymerase (Promega). Thermal cycles were: at 95˚C for 2 min, then 30 cycles at 95˚C for 30 sec, at 62˚C for 30 sec, at 72˚C for l min followed by extension at 72˚C for 7 min.
Results
The group of Plass has reported that dermo1 is methylated in chronic lymphocytic leukemia (CLL) patient samples (16), thus we hypothesis that dermo1 might be regulated through methylation generally. Herein, we assessed methylation status within promoter region of dermo1 in various cancer cell lines by using bisulfite PCR. We mapped the location of three big CpG island (Fig. 1) (criterion: size of CpG island >100 bp, GC content >50.0%, Obs/Exp >0.6) within the dermo1 gene, and the location of the probe (bisulfite PCR) designed to amplify the -631 to -184 bp region of the promoter. BS-PCR analysis of DNA from the selected cancer cell lines (HL60, RS4:11, MDM-BA231, H358 and H1299) indicated that the 430 bp fragment was detectable, and the primer we designed was feasible (Fig. 2) .
If the original DNA is methylated, BS-PCR products could be digested to small fragments by BstUI (enzyme specially targeted at methylated CG ↓ CG). Amplified BS-PCR Figure 1 . Schematic of dermo1 promoter-associated CpG island region, primer used for bisulfite polymerase chain reaction (BS-PCR): (criterion: size of CpG island >100 bp, GC content >50.0%, Obs/Exp >0.6).
products from the selected cell lines (HL60, RS4:11, MDM-BA231, H358 and H1299) were completely cleaved by BstUI (Fig. 3) , only 250 and 50 bp fragments were visualized by agarose gel electrophoresis. This result demonstrated that promoter region of the dermo1 gene was methylated in the analyzed cancer cells. To further confirm that dermo1 was aberrantly methylated in the above cells, we performed BS-PCR sequencing, and verified that the dermo1 gene promoter was extensively methylated in five different cancer cell lines: HL60, RS4:11, MDM-BA231, H358 and H1299 (Fig. 4) .
We designed MSP primer to discriminate between methylated and unmethylated alleles following bisulfite treatment for future sample use due to faster detection. The specificity of two pairs of MS-PCR primers were verified by sequencing the MSP products from HL60 and RS4:11 (Fig. 5) .
We also examined the promoter methylation status of dermo1 in seven human tumor cell lines (HL60, Molm14, MV4-11, RS4:11, MDM-BA231, H358 and H1299) with MSP analysis. We observed that six cell lines (85.7%) had partially methylation, and one cell line (Molm14) had total methylation (14.3%) (Fig. 6A) . We next examined these samples to determine whether dermo1 promoter methylation regulates its expression. Reverse transcription PCR shows that Molm14 cell line did not express dermo1, MV4-11 and RS4:11 cells expressed low basal level of dermo1. However, four cell lines (HL60, MDM-BA231, H358 and H1299) expressed some dermo1 mRNA (Fig. 6B) . 
Discussion
The dermo1 gene is highly conserved in several vertebrates such as humans, mouse, rats, and chicks (8, 18) . It has been shown that dermo1 functions as a potent transcriptional repressor for MyoD and as an anti-apoptotic agent for Mycand p53-dependent cell death (10, 18) , and its methylation is associated with mutated Ig VH genes in CLL cases (16) . dermo1 can also cooperate with activated oncoproteins such as Ras in promoting EMT, which indicates that reactivation of Twist proteins in vivo promotes malignant conversion concomitantly with metastatic dissemination (19, 20) .
However, the precise biological roles of dermo1 during tumorigenesis and its molecular mechanisms of action remain largely unknown. Considering its potential role in development and tumorigenesis, unraveling dermo1 methylation status holds important implications for cancer diagnosis, identification of new targets for therapy, and development of new strategies for clinical management (21) .
The CpG promoter area we investigated is much larger than that used by the Plass group (16), thus providing more information. Our finding shows dermo1 methylation regulation extensively existed in different cancer cells except for CLL. Our data suggest that the methylation of dermo1 promoter might suppress dermo1 gene expression, therefore demethylation therapy might be a promising approach to treat cancer. The MS-PCR analysis of dermo1 also provides an easy way for cancer diagnosis.
Four types of cancer cells in which promoter methylation was detected by MSP partially expressed dermo1 mRNA, indicating that although promoter methylation could be one of the mechanisms regulating expression in cancer cells, there are additional regulatory pathways involved in dermo1 silencing. While more research needs to be done to fully understand the implication of methylation dermo1 in tumorigenesis, the existence of cancer cells with aberrant dermo1 methylation is potentially promising for diagnosis. 
